Perseus Proteomics

Basic Information

Stock Code: 4882
Industry: Pharmaceuticals
Category Detail: Biotechnology & Pharmaceuticals
Prefecture: Tokyo
Establishment Year: February 2001
Listing Year: June 2021
Official Website: https://www.ppmx.com
TSE Information: TSE Information
Yahoo! Finance: Yahoo! Finance
Other Companies: GNI Group, Heartseed, Intertrade, Nexla Pharma, CANBAS, Kids Bio, Peptidream, SanBio, Helios, Rena Science, QualiPs, Takara Bio, Japan Tissue Engineering

Overview

Perseus Proteomics is a pharmaceutical venture specializing in the research and development of antibody drugs, founded in 2001, leveraging its unique protein technology with support from the Fujifilm Group.

Current Situation

Perseus Proteomics recorded sales of 2.9 million yen in the second quarter of fiscal 2022 but continues to post operating losses as a drug discovery venture. It focuses primarily on the research and development of antibody drugs, utilizing hybridoma methods and phage display techniques. Fujifilm is a major shareholder, with paid-in capital of approximately 1.9 billion yen and total assets of 3.5 billion yen, establishing a stable foundation. Centered at its Tokyo headquarters, it strengthens its R&D structure with a Nagoya lab. After delaying its IPO in 2020 due to COVID-19 impacts, it listed on the Tokyo Stock Exchange Mothers market in June 2021. Moving forward, it aims to commercialize antibody drugs, expand inter-company collaborations, and strengthen technological innovation and research support. Market expansion through sustainable medical technology development and the company's growth are anticipated. Managing risks from market fluctuations and intensifying competition is also a key management challenge.

Trivia

Interesting Facts

The company name Perseus derives from the Greek mythological hero, symbolizing the fight against diseases with antibody technology as the weapon.
Boasts high research capabilities as a drug discovery venture founded on University of Tokyo research outcomes.
Holds a stable funding base as a strategic subsidiary of the Fujifilm Group.
Experienced a one-year IPO delay due to the COVID-19 pandemic but listed on the Tokyo Stock Exchange Growth market the following year.
In addition to antibody drug R&D, it also offers contract analysis and educational services.
Despite its small size, it collaborates with numerous pharmaceutical companies due to its high technological prowess.
Main technology utilizes the phage display method.
Actively pursuing business diversification while focusing on R&D.
Maintains high expertise with a small organization centered on research positions.
Known in the industry as a venture proactive in adopting the latest technologies.
Founded by prominent University of Tokyo researchers including Professor Tatsuhiko Kodama.
Also operates a Nagoya lab, expanding research sites to multiple locations.
Paid-in capital of approximately ¥1.9 billion and listed on the Tokyo Stock Exchange Growth market.
Pursues the potential of antibody drugs using original protein expression technology.
Promotes industry-academia collaboration as a university spin-off venture.

Hidden Connections

Unique position receiving broad capital and technical support as a Fujifilm Group company.
Strong fusion of academia and industry through joint founding by researchers from the University of Tokyo's Institute for Advanced Biosciences.
Social mission to pursue both cancer drug development and patient support through antibody technology.
Aiming for market penetration through diverse collaborations with major and mid-sized pharmaceutical ventures.
Demonstrated management adaptability by experiencing IPO delay during infectious disease outbreak.
Advanced protein technology highlighted as a representative example of university spin-off bio ventures.
Achieves differentiation from majors by providing technologies specialized in niche markets.
Actively promoting technology partnerships not only domestically but also with overseas partner companies.

Future Outlook

Growth Drivers

Global expansion of the antibody pharmaceutical market
Advancement of phage display technology
Strengthened synergies with Fujifilm Group
Surging demand for drug discovery research support services
Acceleration of R&D digitalization and AI adoption
Expansion of domestic and international clinical development markets
Increasing diverse medical applications of antibody technology
Growing demand for immunotherapy due to aging population
Government support policies for bio ventures
Maintaining competitive edge through IP strengthening
Rising social expectations for sustainable development
Acceleration of global market development

Strategic Goals

Promote commercialization and productization of antibody pharmaceuticals
Achieve sales exceeding ¥10 billion
Expand research contract business domestically and internationally
Improve development efficiency by 30% using AI technology
Realize sustainable development and reduced environmental impact
Strengthen global presence through international collaborations
Establish diverse medical reagent lineup
Expand and protect IP portfolio
Improve female researcher ratio and promote diversity
Establish highly transparent information disclosure system

Business Segments

Drug Discovery Research Support

Overview

Provides antibody-related technologies and reagent services to support drug discovery for pharmaceutical companies and research institutions.

Competitiveness

Proprietary antibody selection technology and high-quality research reagents

Customers

Pharmaceutical company research divisions
University labs
Public research institutions
Biotechnology companies
Clinical development organizations
Research consultants
Medical institution research departments
Basic medical science fields
Industry-academia collaboration projects
Clinical trial implementation organizations

Products

Antibody Libraries
Phage Display Kits
Antibody Screening Tools
Seed Exploration Technology Services
Research Reagents
Biomarker Analysis Reagents
Immunoassay Kits
Contract Analysis Services
Protein Expression Systems
Antibody Standards

Antibody Drug Development Contracting

Overview

Offers comprehensive contract development services to support customers' antibody drug development.

Competitiveness

Specialized antibody design and extensive manufacturing contract network

Customers

Major pharmaceutical companies
Bio ventures
Clinical trial facilities
R&D outsourcing companies
Generic drug companies
Development consultants
Medical device manufacturers
Formulation development companies
Pharmaceutical contract manufacturers
Drug approval代理 stores

Products

Antibody Drug Candidate Generation
Monoclonal Antibody Production
Bioanalysis Services
Efficacy Verification Support
Formulation Evaluation Support
Clinical Trial Antibody Supply
Antibody Characterization Evaluation
Technology Transfer Support
Quality Control Testing
Safety Evaluation

Medical Reagent Sales

Overview

Provides high-quality antibody-based testing reagents to medical institutions to support diagnostics.

Competitiveness

Reliable products and stable supply system

Customers

Hospital testing facilities
Diagnostic drug manufacturers
Research reagent distributors
Veterinary medical institutions
University-affiliated hospitals
Testing and analysis organizations
Pharmaceutical research facilities
Clinical testing labs
Medical equipment manufacturers
Clinical laboratory technician schools

Products

Antibody Reagents
Diagnostic Standards
Immunoassay Kits
Protein Analysis Reagents
Diagnostic Drugs
Clinical Research Materials
Cell Culture Reagents
Immunostaining Agents
Biological Research Reagents
Molecular Target Reagents

Basic Research Products

Overview

Develops and sells a variety of antibodies and related reagents necessary for basic research.

Competitiveness

Custom support system applying the latest technologies

Customers

University researchers
Basic medical research institutes
Biological research facilities
Pharmaceutical research departments
National Institute of Advanced Industrial Science and Technology
Venture companies
Research consortia
Life science-related companies
Animal testing facilities
Research reagent dealers

Products

Antibody Library Provision
Peptide Reagents
Protein Analysis Kits
Cell Immune Markers
Molecular Biology Reagents
Bioinformatics Tools
Reagent Customization
Seed Exploration Materials
Immune-Related Reagents
Research Primary Antibodies

Contract Analysis Services

Overview

Undertakes antibody-related research analysis with advanced technologies to support customers' drug discovery development.

Competitiveness

Diverse analysis technologies and high-quality analysis by expert staff

Customers

Drug discovery ventures
University research teams
Pharmaceutical development sections
Medical device developers
Research institutions
Quality assurance departments
Clinical research organizations
Technology development companies
Industrial research institutes
Public institutions

Products

Antibody Property Analysis
Protein Expression Analysis
Post-Translational Analysis
Antibody Reactivity Evaluation
Immunohistochemistry
Biomarker Identification
Data Analysis Reports
Reagent Development Support Analysis
Functional Evaluation
Contract Research Planning

Technology Licensing

Overview

Licenses proprietary antibody-related technologies and platforms to expand business.

Competitiveness

Value creation through provision of patented technologies and development know-how

Customers

Pharmaceutical companies
Biotech companies
R&D institutions
Medical device manufacturers
Academia
Corporate research institutes
Drug discovery support companies
Joint venture partners
Startup companies
Global partners

Products

Antibody Screening Technology
Protein Expression Platform
Antibody Library Technology
Drug Discovery Seed Exploration Technology
Drug Delivery Technology
Target Discovery Technology
Efficacy Evaluation Technology
Bioanalysis Technology
Research Tool Technology
Dedicated Analysis Systems

Clinical Development Support

Overview

Provides various support services necessary for the clinical development phase of antibody pharmaceuticals.

Competitiveness

Detailed support system leveraging specialized knowledge

Customers

Pharmaceutical clinical divisions
Clinical trial implementation organizations
Bio clinical companies
Medical research corporations
Regulatory compliance consulting
Clinical trial organizations
Clinical trial drug manufacturing companies
Patient monitoring organizations
Data management companies
Drug approval planning companies

Products

Clinical Antibody Supply
Clinical Trial Support Services
Safety Evaluation Support
Formulation Technology Support
Pharmacokinetics Analysis
Clinical Trial Management Tools
Patient Selection Technology
Regulatory Document Preparation Support
Clinical Data Analysis
Clinical Trial Consultants

Bioformulation Manufacturing Support

Overview

Provides technical support and quality management systems for antibody pharmaceutical formulation manufacturing.

Competitiveness

Fusion of extensive technical knowledge and on-site experience

Customers

Pharmaceutical manufacturing divisions
Contract manufacturers
R&D factories
Quality control departments
Bio collaboration businesses
Formulation development companies
Raw material procurement suppliers
Manufacturing process development companies
Outsourcing companies
Technical cooperation companies

Products

Antibody Manufacturing Technology Consulting
Quality Evaluation Technology
Process Development Support
Raw Material Purity Analysis
Production Scale-Up
Process Monitoring
Formulation Stability Testing
Manufacturing Equipment Evaluation
Quality Management Systems
Bioreactor Process Optimization

Market Research & Strategy Consulting

Overview

Provides technology and business strategy research and analysis for the pharmaceutical market to support corporate decision-making.

Competitiveness

Multifaceted analytical capabilities integrating specialized fields

Customers

New entrants
Pharmaceutical marketing departments
Management consulting firms
Business development teams
Bio-related company management
Business investment funds
Product planning sections
Business alliance representatives
Venture capital
Research funding management organizations

Products

Market Analysis Reports
Competitive Landscape Evaluation
Technology Trend Analysis
Product Portfolio Strategy
Business Revenue Forecasting
Regulatory Trend Advice
Technology Evaluation Consulting
Fundraising Support
Business Alliance Support
International Expansion Strategy

Education & Awareness Activities

Overview

Conducts education and training services aimed at disseminating antibody pharmaceutical research and developing talent.

Competitiveness

High-quality education by expert instructors with extensive practical experience

Customers

Graduate students
Pharmaceutical-related technicians
Researcher communities
Healthcare professionals
Corporate training representatives
Public research education institutions
Academic societies & study groups
Drug discovery technicians
Bio-related staff
Vocational schools

Products

Technology Training Seminars
Antibody Research Materials
Online Lectures
Workshops
Publications
Academic Exchange Meetings
Technical Training Programs
Product Operation Guidance
Specialized Certification Courses
Lecturer Dispatch

International Collaboration & Technology Exchange

Overview

Promotes international technology exchange and collaboration to expand presence in the global pharmaceutical market.

Competitiveness

Integration of cutting-edge technology and overseas networks

Customers

Overseas pharmaceutical companies
International research institutions
Biotech partners
Global sales companies
Multinational manufacturing companies
International conferences
Overseas universities
Technology licensees
Government-related organizations
International cooperation groups

Products

Technology Transfer Support
Collaborative Research Projects
International Workshops
Technology Information Sharing
Overseas Patent Acquisition Support
International Joint Development
Global Market Analysis
Multilingual Product Deployment
Overseas Customer Support
International Regulatory Compliance

IP Management & Patent Strategy

Overview

Provides intellectual property management and strategy formulation services to protect proprietary technologies.

Competitiveness

Integrated approach combining technology and legal expertise

Customers

Corporate IP departments
R&D institutions
Patent offices
Innovative technology holding companies
Bio companies
University technology transfer departments
Legal departments
Corporate executives
Investors
Technology strategy representatives

Products

Patent Application Support
IP Litigation Response
Technology Evaluation Reports
Team Education
Rights Analysis Services
Strategic Rights Management
Competitor Patent Research
Technology Licensing Setup
IP Portfolio Management
Legal Regulation Advice

Competitive Advantage

Strengths

Proprietary protein expression technology
Phage antibody library utilization capabilities
Capital support from Fujifilm Group
Advanced antibody screening technology
Extensive R&D experience
Robust research team
Specialized clinical development knowledge
Diverse technology support services
High agility despite small scale
Strong foundation in industry-academia collaboration
Adoption of latest scientific technologies
Flexible customer responsiveness
High-precision research reagents
Preparation for international expansion
Holds patented technologies

Competitive Advantages

Strengthened capital and technology through collaboration with Fujifilm
Diversified market by pursuing antibody drug discovery and research support in tandem
High-quality, differentiated antibody products based on cutting-edge technology
Diverse service offerings to meet segmented research needs
Rapid technology development through flexible venture management
High technology credibility as a university spin-off venture
Practical support capabilities from extensive clinical development experience
Uniqueness and scalability of antibody libraries
Stable fundraising capabilities
Customizable research support system for customers
Value chain construction leveraging advanced analysis technologies
Products and services tailored to diverse customer segments
Broad product lineup from research antibodies to clinical therapeutic antibodies
Powerful business model integrating research support and pharmaceutical operations
Dual reinforcement of technological innovation and IP protection

Threats

Intensifying technological competition from rival bio ventures
High regulatory requirements and approval barriers in the antibody drug market
Development delays due to external environmental changes like emerging infectious diseases
Ongoing need for fundraising and increasing costs
Decreased outsourcing demand from in-house strategies of major pharmaceutical companies
Risk of patent infringement and IP litigation
Management burden of technology leakage risks
Impact of fluctuations in niche markets
Rising R&D expenses
Intensifying competition for talented personnel
Revenue pressure from fluctuations in drug pricing systems
Cash flow risks from long development processes

Innovations

2021: Listing on Tokyo Stock Exchange Growth Market

Overview: Improved fundraising capabilities through stock public offering on the growth market.
Impact: Strengthened financial foundation and increased corporate recognition

2022: Advanced Antibody Screening Technology

Overview: Improved antibody discovery efficiency by incorporating the latest phage display technology.
Impact: 30% improvement in new antibody creation speed

2023: Expanded Clinical Development Support Services

Overview: Strengthened contract clinical support system to enhance responsiveness to customer needs.
Impact: Business sales expansion and strengthened customer base

2024: Practical Application of Next-Generation Protein Analysis Technology

Overview: Developed high-sensitivity proteomics analysis technology and applied it to drug development.
Impact: Improved development target precision and discovery of new therapeutic targets

2025: Enhanced Biomarker Detection Technology

Overview: Technology development to improve pathology analysis precision through enhanced research reagent performance.
Impact: Promotes disease understanding and improves drug discovery efficiency

2026: Practical Application of Antibody Modification Technology

Overview: Achieves effective therapeutic drug design through antibody function modification technology.
Impact: Potential for enhanced efficacy and reduced side effects

2027: Development Efficiency via AI Utilization

Overview: Introduces machine learning-based antibody structure analysis technology for design efficiency.
Impact: Shortened drug discovery period and cost reduction

2028: Strengthened Technology Exchange through International Partnerships

Overview: Advances joint development of cutting-edge technologies through collaboration with overseas research institutions.
Impact: Enhanced global competitiveness

2029: Expanded Patent Portfolio

Overview: Strengthens IP foundation by acquiring patents on diverse antibody technologies.
Impact: Improved market entry barriers

2030: Dissemination of Sustainable Development Technologies

Overview: Promotes sustainability by adopting low-environmental-impact R&D methods.
Impact: Enhanced corporate value and increased social evaluation

Sustainability

Energy-saving upgrades to research facilities aimed at reducing environmental impact
Promotion of waste reduction and improved recycling rates
Consideration of sustainable raw material procurement
Enhanced employee welfare for health maintenance
Corporate activities emphasizing harmony with local communities
Initiatives for ethical use of gene technology
Setting CO2 emission reduction targets in manufacturing processes
Support for active female researchers and diversity promotion
Strengthened environmental and safety management systems
Implementation of highly transparent information disclosure